FDA Says Cepheid's MRSA Dx Is Of 'Moderate Complexity' | GenomeWeb
NEW YORK (GenomeWeb News) — The US Food and Drug Administration has determined that Cepheid’s methicillin-resistant Staphylococcus aureus test is of “moderate complexity” under its Clinical Laboratory Improvement Amendments guidelines, the company said today.
Cepheid said that the categorization will enable the Xpert MRSA test to be used both within and outside traditional hospital labs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.